Newer Anticoagulant Therapies

Newer Anticoagulant Therapies
Presentation by:Chris Ferrell MT(ASCP), CLS/H(NCA)

Special Coagulation Lead
Harborview Medical Center
University of Washington

Heparin Therapy
Lupus Anticoagulant and PTT
Monitoring Heparin Therapy in Patients with LA
Warfarin Therapy
Lupus Anticoagulant and Protime
Monitoring Coumadin Therapy in Patients with LA
Low Molecular Weight Heparin
Antithrombin
Thrombin
Unfractionated Heparin
Pentasaccharide
Antithrombin
Factor Xa
Pentasaccharide
LMWH Comparisons
Tinzaparin
Reviparin
Nadroparin
Enoxaparin
Dalteparin
Ardeparin
Advantages
FDA Approved Indications of LMWHs
Total knee replacement
Total hip replacement
General surgery
LMWH Administration
PTT and LWMH
LMWH Comparisons
Low Molecular Weight Heparin
Other Tests to Monitor Heparin
Problems with Monitoring Heparin Therapy with PTT’s
Why Use LMWH vs. UFH?
Heparin Induced Thrombocytopenia
What Is It?
Heparin Induced Thrombocytopenia
HIT Testing
How Do You Diagnose It?
HIT Testing by Aggregometry
Light source
Positive HIT Test
Patient Plasma
Heparin Induced Thrombocytopenia
Advances in Anticoagulation
Direct Thrombin Inhibitors
Hirudin and Derivatives
Thrombin and Hirudin
Direct Thrombin Inhibitors
Hirudin and Derivatives
Direct Thrombin Inhibitors Hirudin and Derivatives
Direct Thrombin Inhibitors
Clinical Trials of Direct Thrombin Inhibitors
Direct Thrombin Inhibitors
Effect on Laboratory Testing
Low Molecular Weight Heparin
Fondaparinux
Inhibition of VIIa/TF
Tissue Factor Pathway Inhibitor
Enhanced Protein C Pathway
Enhancement of the fibrinolysis
Advances in Anticoagulation
Platelet Function Inhibitors
Ideal Anticoagulant

Newer Anticoagulant Therapies,ppt